Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 213.0
(3.15%)
TWD 213.0
(3.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.95 Billion TWD | 15.89% |
| 2022 | 14.63 Billion TWD | 15.68% |
| 2021 | 12.64 Billion TWD | 17.9% |
| 2020 | 10.72 Billion TWD | 16.94% |
| 2019 | 9.17 Billion TWD | 42.71% |
| 2018 | 6.42 Billion TWD | 0.08% |
| 2017 | 6.42 Billion TWD | 8.83% |
| 2016 | 5.9 Billion TWD | 6.89% |
| 2015 | 5.52 Billion TWD | 139.04% |
| 2014 | 2.31 Billion TWD | 250.81% |
| 2013 | 658.48 Million TWD | 30.87% |
| 2012 | 503.15 Million TWD | -5.46% |
| 2011 | 532.2 Million TWD | -9.82% |
| 2010 | 590.18 Million TWD | -2.74% |
| 2009 | 606.82 Million TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.19 Billion TWD | 22.79% |
| 2024 Q2 | 4.74 Billion TWD | 12.98% |
| 2023 Q4 | 3.41 Billion TWD | -25.24% |
| 2023 Q2 | 4.44 Billion TWD | -1.81% |
| 2023 Q3 | 4.57 Billion TWD | 2.96% |
| 2023 FY | 16.95 Billion TWD | 15.89% |
| 2023 Q1 | 4.52 Billion TWD | 42.64% |
| 2022 FY | 14.63 Billion TWD | 15.68% |
| 2022 Q3 | 5.38 Billion TWD | 85.17% |
| 2022 Q4 | 3.17 Billion TWD | -41.15% |
| 2022 Q1 | 3.16 Billion TWD | 12.79% |
| 2022 Q2 | 2.91 Billion TWD | -7.94% |
| 2021 Q3 | 3.05 Billion TWD | -11.73% |
| 2021 Q4 | 2.8 Billion TWD | -8.34% |
| 2021 FY | 12.64 Billion TWD | 17.9% |
| 2021 Q1 | 3.32 Billion TWD | 6.18% |
| 2021 Q2 | 3.46 Billion TWD | 4.2% |
| 2020 Q1 | 1.96 Billion TWD | -37.26% |
| 2020 Q4 | 3.13 Billion TWD | 8.48% |
| 2020 Q2 | 2.67 Billion TWD | 36.4% |
| 2020 Q3 | 2.88 Billion TWD | 7.82% |
| 2020 FY | 10.72 Billion TWD | 16.94% |
| 2019 Q2 | 1.89 Billion TWD | -13.23% |
| 2019 Q4 | 3.12 Billion TWD | 58.8% |
| 2019 FY | 9.17 Billion TWD | 42.71% |
| 2019 Q1 | 2.18 Billion TWD | 26.71% |
| 2019 Q3 | 1.96 Billion TWD | 4.02% |
| 2018 Q2 | 1.63 Billion TWD | 9.77% |
| 2018 FY | 6.42 Billion TWD | 0.08% |
| 2018 Q4 | 1.72 Billion TWD | 8.94% |
| 2018 Q3 | 1.58 Billion TWD | -3.31% |
| 2018 Q1 | 1.48 Billion TWD | -18.64% |
| 2017 Q2 | 1.57 Billion TWD | 9.84% |
| 2017 FY | 6.42 Billion TWD | 8.83% |
| 2017 Q4 | 1.83 Billion TWD | 15.96% |
| 2017 Q1 | 1.43 Billion TWD | -2.92% |
| 2017 Q3 | 1.57 Billion TWD | 0.11% |
| 2016 Q1 | 1.42 Billion TWD | -3.22% |
| 2016 Q4 | 1.47 Billion TWD | 5.4% |
| 2016 Q3 | 1.4 Billion TWD | -11.96% |
| 2016 FY | 5.9 Billion TWD | 6.89% |
| 2016 Q2 | 1.59 Billion TWD | 11.86% |
| 2015 FY | 5.52 Billion TWD | 139.04% |
| 2015 Q3 | 1.41 Billion TWD | 5.99% |
| 2015 Q4 | 1.47 Billion TWD | 3.89% |
| 2015 Q2 | 1.33 Billion TWD | 3.32% |
| 2015 Q1 | 1.29 Billion TWD | 95.86% |
| 2014 Q1 | 128.01 Million TWD | -40.24% |
| 2014 Q4 | 660.89 Million TWD | 13.0% |
| 2014 Q3 | 584.86 Million TWD | 303.15% |
| 2014 Q2 | 145.07 Million TWD | 13.32% |
| 2014 FY | 2.31 Billion TWD | 250.81% |
| 2013 Q1 | 159.78 Million TWD | 18.4% |
| 2013 Q4 | 214.21 Million TWD | 40.51% |
| 2013 Q3 | 152.45 Million TWD | 15.48% |
| 2013 Q2 | 132.02 Million TWD | -17.37% |
| 2013 FY | 658.48 Million TWD | 30.87% |
| 2012 FY | 503.15 Million TWD | -5.46% |
| 2012 Q1 | 102.08 Million TWD | -40.19% |
| 2012 Q2 | 115.31 Million TWD | 12.96% |
| 2012 Q3 | 150.8 Million TWD | 30.77% |
| 2012 Q4 | 134.95 Million TWD | -10.51% |
| 2011 Q1 | 121.37 Million TWD | -24.7% |
| 2011 Q2 | 115.8 Million TWD | -4.6% |
| 2011 Q3 | 124.34 Million TWD | 7.38% |
| 2011 Q4 | 170.68 Million TWD | 37.26% |
| 2011 FY | 532.2 Million TWD | -9.82% |
| 2010 Q3 | 140.23 Million TWD | -7.18% |
| 2010 Q2 | 151.08 Million TWD | 9.74% |
| 2010 Q1 | 137.67 Million TWD | 0.0% |
| 2010 Q4 | 161.19 Million TWD | 14.95% |
| 2010 FY | 590.18 Million TWD | -2.74% |
| 2009 FY | 606.82 Million TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Grape King Bio Ltd | 10.63 Billion TWD | -59.485% |
| Standard Chem & Pharm CO., LTD. | 6.23 Billion TWD | -171.772% |
| Maywufa Company Ltd. | 1.3 Billion TWD | -1203.736% |
| ScinoPharm Taiwan, Ltd. | 3.18 Billion TWD | -432.251% |
| LIWANLI Innovation Co., Ltd. | 38.88 Million TWD | -43508.329% |
| YungShin Global Holding Corporation | 7.02 Billion TWD | -141.294% |
| PhytoHealth Corporation | 162.48 Million TWD | -10336.381% |
| SCI Pharmtech, Inc. | 1.2 Billion TWD | -1308.283% |
| Formosa Laboratories, Inc. | 4.36 Billion TWD | -288.904% |
| PharmaEssentia Corporation | 5.1 Billion TWD | -232.144% |
| Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | -19.422% |